All Comparisons
GHK-Cu vs BPC-157
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
GHK-Cu: FBPC-157: C
| Attribute | GHK-Cu | BPC-157 |
|---|---|---|
| Category | Skin & Tissue Repair | Healing & Recovery |
| Evidence Rating | F — No Regulatory Activity | C — Phase I–II Clinical Trials |
| Clinical Status | Available in cosmetic formulations; no drug approval | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. It stimulates collagen, elastin, and glycosaminoglycan synthesis, modulates metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), attracts i... | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors... |
| Half-Life | ~30 minutes plasma | ~15 min IV (animal data); oral activity persists 24+ hours |
| Bioavailability | — | IM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation |
| Molecular Weight | ~403.9 g/mol | ~1419.5 g/mol |
| WADA Status | Not Listed | Prohibited |
| Dosing | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area, SC: Once daily; Topical: 1–2x daily (Subcutaneous, Topical (cream/serum), or Intradermal (microneedling)) | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials, Once daily (Subcutaneous (preferred), Intramuscular, or Oral) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Available as a cosmetic ingredient (Copper Tripeptide-1). Not FDA-approved as a drug. Removed from FDA Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026. No IND application filed for injectable use. | Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.